24-25th november, Mövenpick hotel zürich-regensdorf, Zurich, Switzerland Email us at info@csint.com to book a meeting with our experts! ...

The growth in the biosimilar market since 2006 has been significant. Biosimilars have no meaningful clinical differences between the...

Csi is attending clinical trial supply europe 2021 CSI is attending Clinical Trial Supply Europe Virtual Conference. We want to use this...

Innovation in oncology drug development is granting cancer patients access to life-changing therapies. The industry continues to conduct...

The development of the coronavirus vaccine has dominated the pharmaceutical industry over the past year With the Pfizer-BioNTech vaccine...

For young people, learning to manage the condition is so important. There is a wealth of information out there that can help youths...

Oncology products monopolise the list of best-selling drugs. With a huge range of indications that is only growing, therapies become more specific to tumour or cell pathologies and increasing patient numbers. Several oncology products now have ‘blockbuster’ status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster produc